Category: Government


Visit to England: What Did We Learn? 
Posted on Apr 04, 2017

We just returned from a brief trip to England, where we met with a client, plus a few friends and colleagues. Over several meetings and meals, three issues consistently came up during conversation: Terrorism, Brexit and Trump. Terrorism – The United Kingdom is no stranger to terrorism, as this lengthy list of terrorist attacks in London illustrates. The

What Will a Trump Administration Mean for Our Industry? 
Posted on Nov 21, 2016

Few of us will soon forget waking up in Cologne to the news that we will soon have a “President Trump” in the Oval Office in a few months. So, what will a Trump Administration mean for our industry? The short answer is “Who knows?”  For better or for worse, we Americans have elected not

The Life Sciences in Wyoming – Part One of Three 
Posted on Oct 30, 2014

 Is this the next major biotech cluster in the US? Wyoming? Yes, Wyoming. Why not? In the First of a Three-part series, our guest blogger Dr. Garrett Lindemann (@WyomingScience) discusses the growing life sciences industry in the State of Wyoming. All states in the US would love to have a bubbling life science industry like Massachusetts

Inversions: Alive or Dead? 
Posted on Oct 09, 2014

  The reports of my death have been greatly exaggerated. Mark Twain In July, we summarized the issue of companies acquiring other companies in tax-friendly countries. These so-called “inversions” were not a new phenomenon, but their interest (at least in our industry) reached a fevered pitch this year. Can This Continue? This was a question we

Pfizer Biocon signals the end for biosimilars? Hardly… 
Posted on Mar 15, 2012

Earlier this week we learned that Pfizer will return to Biocon rights to biosimilar versions of various insulin derivatives: As of March 12, 2012, all rights licensed to Pfizer will revert to Biocon, and all insulin distributed under the brand name UniviaTM and GlarviaTM will be commercially available from Biocon Ltd. only, and will be

Dublin Calling 
Posted on Sep 26, 2011

What do companies such as Twitter, Facebook, and Google have in common with Pfizer, Amgen, BioMarin, Alkermes, and Jazz Pharmaceuticals? Dublin. All of them have set up international operations in Dublin, in part to reduce their tax bill and access the local, skilled biotech workforce.  The Twitter/Google/Facebook article is here, while biotech in Ireland is summarized here.  Most of

A Rainy Day for Spanish Pharmacists 
Posted on Aug 26, 2011

Yesterday’s Financial Times reported that pharmacists in Spain are struggling to continue operating their businesses due to a lack of payment from the Regional governments. “We depend 80 to 90 per cent on the health system, and it’s the first time they’ve stopped paying,” says Ms Espinosa, who is president of the regional pharmacists’ federation.

Biosimilars: Are We There Yet? 
Posted on Aug 04, 2011

Today’s New England Journal of Medicine contains a short article by Kozlowski et al entitled Developing the Nation’s Biosimilars Program (link to PDF). Here, the authors attempt t provide a framework for answering a deceptively complex question, namely: How similar is similar enough when it comes to the substitution of complex biologic drug products in

Update: Pain continues to be painful 
Posted on Apr 22, 2011

This week we learn that two novel pain medications will never see the light of day: Novartis had reached the market with the COX-II inhibitor Prexige (rebranded as the unusually positive name of Joicela), until regulators forced Novartis to pull the drug from the market in 2007. Taking a biomarker/ personalized medicine approach did not

Impressions from Natural Products ExpoWest 2011 
Posted on Mar 15, 2011

This weekend was spent attending the Natural Products ExpoWest convention in Anaheim on behalf of a few of our clients. This was our first time attending this conference. Aside from the great food in Hallway E, we spent our time representing our clients and learning a lot. Our impressions: 1. There is an increasing demand for

More Government Involvement in Pharma Industry 
Posted on Jan 04, 2011

The past few months have seen a number of reports describing how national governments are using policy to spur local pharmaceutical industry growth. We have already described examples from Brazil, Russia, and Russia again. Today we learn that the Indian government is reportedly looking to cap foreign direct investment in pharmaceutical (and related) companies to

Brazil’s prescription for pharma: More Government involvement 
Posted on Dec 23, 2010

Earlier this week we wrote about the emerging trend of increasing state government involvement in the pharmaceutical industry. Today we learn about what the government in Brazil is doing. Of interest: The state-led complex’s future evolution poses challenges for Brazil’s health system and domestic producers, as well as for western companies increasingly eager to tap

Google Plus   Facebook   Twitter
Powered By : Supra International Inc.